

Idiopathic environmental intolerances (IEI): From molecular epidemiology to molecular medicine

C De Luca¹, G Scordo², E Cesareo¹, D Raskovic¹, G Genovesi³ & L Korkina^{1*}

Laboratory of Tissue Engineering & Cutaneous Pathophysiology¹, Istituto Dermatologico dell'Immacolata, Rome, Italy

Department of Medical Sciences - Clinical Pharmacology², University Hospital, Uppsala, Sweden;

Department of Medical Pathophysiology³, Policlinico Umberto I, University of Rome "La Sapienza", Rome, Italy

Inherited or acquired impairment of xenobiotics metabolism is a postulated mechanism underlying environment-associated pathologies such as multiple chemical sensitivity, fibromyalgia, chronic fatigue syndrome, dental amalgam disease, and others, also collectively named idiopathic environmental intolerances (IEI). In view of the poor current knowledge of their etiology and pathogenesis, and the absence of recognised genetic and metabolic markers of the diseases. They are often considered "medically unexplained syndromes". These disabling conditions share the features of poly-symptomatic multi-organ syndromes, considered by part of the medical community to be aberrant responses triggered by exposure to low-dose organic and inorganic chemicals and metals, in concentrations far below average reference levels admitted for environmental toxicants. A genetic predisposition to altered biotransformation of environmental chemicals, drugs, and metals, and of endogenous low-molecular weight metabolites, caused by polymorphisms of genes coding for xenobiotic metabolizing enzymes, their receptors and transcription factors appears to be involved in the susceptibility to these environment-associated pathologies, along with epigenetic factors. Free radical/antioxidant homeostasis may also be heavily implicated, indirectly by affecting the regulation of xenobiotic metabolizing enzymes, and directly by causing increased levels of oxidative products, implicated in the chronic damage of cells and tissues, which is in part correlated with clinical symptoms. More systematic studies of molecular epidemiology, toxico- and pharmaco-genomics, elucidating the mechanisms of regulation, expression, induction, and activity of antioxidant/detoxifying enzymes, and the possible role of inflammatory mediators, promise a better understanding of this pathologically increased sensitivity to low-level chemical stimuli, and a solid basis for effective individualized antioxidant- and/or chelator-based treatments.

Keywords: Antioxidants, Chelators, Genetic polymorphism, Idiopathic environmental intolerances, Redox imbalance

Introduction

Idiopathic environmental intolerances (IEI)

Pioneer modern studies on hypersensitivity to chemicals date back to the mid 1950s, although reports existed since late '80 about a condition defined as *neurasthenia*¹. During the last decades, concern for environmental intolerances has been rising, partly due to increased attention to the pathogenetic role of pollution and stressful lifestyles. A consistent number of studies on different environment-associated idiopathic conditions, including multiple chemical sensitivity (MCS), fibromyalgia (FM), chronic fatigue syndrome (CFS), sick building syndrome (SBS), and others, has therefore appeared². To address this wealth of inhomogeneous clinical data, the World Health Organization has labelled as "idiopathic

environmental intolerances" (IEI) those multi-organ conditions³, with special reference to MCS. They are described as aberrant responses to a wide spectrum of potential environmental-borne organic or inorganic chemicals, through airborne or other routes of exposure. The onset of clinical symptoms connected with IEI is related to different physical, chemical or biological factors mainly of environmental origin, such as xenobiotic chemicals and metals, radiations, iatrogenic factors, specific food, microbial and environmental allergens, and endotoxins. Majority the symptoms are overlapping among the different chronic idiopathic conditions of MCS, FM, CFS, SBS, irritable bowel syndrome (IBS), Persian Gulf War veteran syndrome, "amalgam disease", electric hypersensitivity, burn-out syndrome, etc.^{4,5} (Table 1). Moreover, CFS, FM and the Gulf War syndrome show specific markers and clinical signs, which are co-morbid with autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis^{6,7}. Nevertheless, the question as whether IEI have to be

*Correspondent author

Telephone: +3906 66464258

Fax: +3906 66464254

E-mail: l.korkina@idi.it

considered diseases or plain clusters of symptoms has remained unanswered so far^{8,9}, since patients rarely display recognized dysfunctions of the immune system, or IgE-based allergic reactions.

Due to the lack of clear-cut diagnostic criteria and absence of proven pathogenic mechanisms, these diseases remain in most cases neglected by the medical community, which is unable to offer any therapeutic advice. This has generated the collective label of “medically unexplained symptoms”^{9,10}. The absence of therapeutic guidelines leaves space for unregulated and unrecognized treatment protocols, devoid of satisfactory levels of safety, compliance and clinical efficacy assessments, raising further ethical issues for the medical community. Main difficulties towards a clinical consensus about these pathologies lie in the wide array of symptoms allegedly linkable to environmental triggers exposure, in the diversity of subjects affected, reacting on the basis of individual sensitivity. The large spectrum of possible triggers (Table 2) and the absence of dose-dependent reactions also generate methodological difficulties and bias in provocation studies. Finally, there exist conceptual

difficulties in attributing a disease *status* to chemico-physical stimuli delivered in low concentrations, far below the respective reference levels well established for environmental toxicants. In spite of all documented scepticism, the need to address these issues systematically, to provide patients complaints

Table 1—Symptoms characterizing idiopathic environmental intolerances (IEI).

Symptom classification ¹	Syndrome
Head/eye-related	MCS – GWV – CFS – FM – SBS – SHS – electric hypersensitivity
Cognitive / Behavioural	MCS – GWV – CFS – SBS – SHS – electric hypersensitivity
Affective	MCS – GWV – CFS – electric hypersensitivity – dental amalgam disease
Neuromuscular	MCS – GWV – FM – CFS
Musculoskeletal	MCS – GWV – FM – CFS
Skin-related	MCS – GWV – electric hypersensitivity – SBS – SHS
Genitourinary	MCS – GWS – burnout syndrome
Gastrointestinal	MCS – GWS – IBS – FM – electric hypersensitivity
Heart/Chest-related	MCS – GWV – CFS
Airway or mucous membrane	MCS – GWV – SBS – SHS – dental amalgam disease – electric hypersensitivity
Immunological	CFS – FM – MCS/ – dental amalgam disease – burnout syndrome

¹According to Miller and Piroda, modified
MCS = multiple chemical sensitivity; IEI = idiopathic environmental intolerances; CFS = chronic fatigue syndrome; FM = fibromyalgia; IBS = irritable bowel syndrome; SBS = sick building syndrome; SHS = sick house syndrome; GWV = Gulf War Veterans

Table 2—Triggers implicated in the symptom onset and recurrence in the subjects with idiopathic environmental intolerances (IEI).

Type of Trigger	Syndrome
Chemical	
All perfumed substances	MCS – GWV
Volatile organic solvents	MCS – CFS – SBS – SHS – GWV
Petroleum-based products	MCS
Smokes (tobacco, smog, vehicle exhaust, barbecue grill, etc.)	MCS – GWV
Pesticides, agricultural chemicals	MCS
Chlorinated water	MCS
Heavy metals	dental amalgam disease
Cosmetics/soaps	MCS
Perfumes / Deodorizers	MCS
Detergents (all)	MCS
Household chemicals/detergents/bleachers	MCS
Fresh ink/toner/office machines	MCS – CFS – SBS
Aldehydes	MCS
Fabric products	MCS – SBS – SHS
Carpet products	MCS
Building materials / glues / paints	MCS – SBS – SHS
Selected foods	MCS – IBS
Anaesthetics	MCS – burnout syndrome
Psychotropic drugs	MCS
Anticancer chemotherapies	MCS – CFS
Other pharmaceutical drugs	MCS – FM – CFS
Biocompatible materials including nanoparticles and silicone	MCS- FM-CFS
Biological	
Fungal antigens and fungal toxins	MCS – CFS
Yeasts and yeast antigens	IBS
Viral and bacterial infections	FM – CFS
Single or multiple vaccinations	FM – CFS – GWV
Physical	
Electro-magnetic fields	electric hypersensitivity
Telephone and wireless lines	electric hypersensitivity
Video display units	electric hypersensitivity
Irradiations (UVR, XR, Vis)	MCS – CFS – FM
Psychological	
Stressful events	MCS – FM – CFS – burnout syndrome – GWV – IBS
Panicogenic triggers	MCS – FM – CFS

For legend see Table 1

with adequate responses, has been emphasised in the last two decades by the medical community¹¹.

Multiple chemical sensitivity—It is described as a multi-organ condition, where recurring symptoms are muscular weakness and fatigue, confusion and memory loss, minor and major depression, general anxiety, panic disorders and post-trauma distress, respiratory distress, chronic bronchitis and asthma, gastrointestinal tract malfunction, and migratory joint pains⁵. Exposure to even negligible concentrations of common odorous substances, including organic volatile compounds, perfumes, fresh paint, cleaning chemicals, print and toners, new carpeting, and numerous other products, are self-reported as connected to the onset and perpetuating of recurrence of symptoms by hypersensitive MCS patients^{12,13}. A particular role of olfactory function is under debate¹⁴. The diagnosis is set on the basis of anamnestic criteria and thorough enquiry on possible trigger exposure^{15,16}. Due to the prevalence of neurologic impairment, and lack of recognized molecular/biochemical markers for MCS, clinicians incline to classify it among the somatoform disorders or other psychiatric disturbances, on the basis of several studies demonstrating unsatisfactory results of provocation studies^{17,18}.

Fibromyalgia—is a chronic pain syndrome, characterized by widespread inflammatory rheumatic disease with non-articular musculoskeletal pain, acute febrile illness, paresthesia, fatigue, primary sleep disorders, memory and concentration impairment¹⁹, major depressive disorder, migraine, and irritable bowel syndrome²⁰, often leading to working and social inability. The unavailability of specific anatomic, histological or molecular disease markers complicates the diagnosis. Environmental factors may trigger the development of the chronic pain disorders in individuals with a genetic predisposition²¹. Intolerance to certain foods and chemicals has also been implied in FM onset.²²

Chronic Fatigue Syndrome—It is diagnosed on the basis of unexplained disabling fatigue lasting for at least 6 months and not healing with rest, along with several non-specific accompanying symptoms, including disordered sleep physiology and non-restorative sleep syndrome, diffuse myalgia, cognitive and behavioural impairment²³. The pathophysiological mechanism of CFS is still unclear. Common molecular and cellular features of the disease include altered cytokines profiles, decreased function of natural killer cells, presence of

autoantibodies, and a reduced response of T cells to mitogen and other specific antigens²⁴. Aspects of cytokine and cellular immune functions are shown to be related to the sleep-wake system²⁵. The activation of peripheral, central inflammatory and oxidative stress pathways has been recently implied in the etiology of CFS functional symptoms²⁶.

Amalgam disease—The disease is a widely controversial disabling condition, occurring in allegedly metal sensitive subjects, who carry dental amalgam fillings, which contain almost 50% mercury, along with tin-copper-silver and zinc. These materials, used since almost two centuries in dental care, release Hg vapours, though in daily doses far lower than those known to induce neurological symptoms²⁷. This potential Hg chronic intoxication has been connected with a wide variety of symptoms, ranging from oral mucosal and cutaneous signs, to persistent fatigue and autoimmune diseases. Few evidences have also linked dental amalgam to increased risk of multiple sclerosis, the association with Alzheimer or Parkinson disease being far less documented²⁸. Studies on the dentist category have neither documented abnormal death or disease rates, nor any disability susceptible of association with Hg vapours²⁹. In particular, no consistent associations were found between urinary Hg concentration, or the chronic index of Hg exposure, and any category of neurological symptoms³⁰. Till date, this disabling complex of symptoms remains unrecognized by both clinical community and legal entities.

Electro-magnetic hypersensitivity—This condition is perceived as consequent to exposure to environmental electro-magnetic stressors³¹, followed by recovery through the complete isolation from triggers. Subjects complain functional symptoms of the nervous system, i.e. dizziness, fatigue, headache, difficulties in concentration, memory problems, anxiety, depression, respiratory and gastrointestinal symptoms, eye and vision symptoms, palpitations, chronic fatigue, fibromyalgia, skin inflammatory and allergic reactions of face, hands and forearms, and other disorders, in the absence of organic pathological signs. This syndrome is subjectively attributed to the exposure to frequencies in the radio, microwave, kilohertz, and extremely low-frequency ranges of electro-magnetic fields or radiofrequencies, including the so-called “dirty electricity”, that is the pollution due to poor isolation of electric wires and telephonic lines, wireless devices, wi-fi, etc., though no

conclusive demonstration of causal relationship has been drawn so far. These EMF sources vary considerably but are in most cases, far below levels known to cause physiological changes in animal models³². Most of the initial reports from Scandinavian authors deal with dermatological symptoms, subjective, such as itching or burning, and objective, i.e. redness and dryness. These symptoms appear after individuals begin working with video display units, and decrease during absence from work³³. Electric pollution has been connected in anecdotic studies encouraging deeper investigation, to increased risk of chronic and degenerating diseases, including asthma, diabetes, and multiple sclerosis³⁴. As in the case of Hg intoxication, convincing evidences are available only on acute and chronic health disorders deriving from professional exposures to high intensity fields, in electric power plants,³⁵ but no data are available on sub-acute exposures below recommended reference levels, occurring in the civil life³⁶. In addition, data available on the exposure levels self-reported by subjects, or evaluated in studies, are extremely meager. One Swedish study tried to connect perceived fatigue to alterations in cholinesterase activity, finding no correlation³⁷. Several controlled provocation studies failed to discriminate between healthy subjects and subjects claiming to be hyper-sensitive to electric or phone signals, in perceiving exposure to low-dose effective or sham triggers^{38,39}. In general, case-control studies, as well as some good but limited double-blind trials, have not found any clear relationship between claimed symptoms and exposure to EMFs⁴⁰. In spite of controversial results, the concern of physicians in some countries seems to be widespread^{41,42}.

Here again, as in the other conditions described, the almost complete absence of consistent pathophysiological markers, and of validated tests, is the main hindrance to the diagnostic assessment of a perceived disease that can often result invalidating. Various factors have been identified as methodological bias in the provocation studies on IEL. In the case of electric hypersensitivity these factors include inappropriate selection of statistical power, effect of background EMF, inappropriate lag-time between trigger administration and effect monitoring, etc⁴³. Psychological conditioning through media information may represent a bias, as well as the frequently occurring patient's dissatisfaction for mainstream medical approaches⁴⁴, and therefore

psychological factors should better be included in data analysis⁴⁵.

Environmental toxicity: Impairment of the chemical defensive system

The exposure to environmental pollutants and toxicants is a crucial challenge for the human metabolism which has to adapt not only to the chronic non-physiological load of conventional compounds, such as cosmetics, detergents, preserving agents and eccipients, pharmaceutical drugs, but also to entirely new molecules, e.g. slow degrading nanomaterials for medicinal use⁴⁶.

A concerted action of constitutive and inducible, strictly regulated, protective pathways enables adaptation to the rapidly changing environment. This metabolic system defending towards chemicals has presumably evolved very early in primitive eucariots and lower plants, before immune system developed to handle high-molecular weight antigenic molecules, microbes and foreign cells. The chemical defensive system detoxifies low-molecular weight organic and inorganic compounds, including heavy metals, as well as endogenous non-protein signaling molecules, mediators of inflammation, degradation products, and toxic by-product of cellular metabolism⁴⁷.

Recent advances in toxicogenomics have highlighted the role of inherited genetic traits in the individual susceptibility to both xenobiotics and toxic endogenous metabolites⁴⁸. Evolutionary, a complex array of gene families codes for enzymes of specific molecular pathways has specialised to metabolize and clear toxic chemical substances, and to repair molecular consequences of chemical damage. Reactive oxygen species (ROS) are a active part of the detoxification process, both in exposed epithelia and in internal tissues, with a double role of biosensors of environmental/endogenous stressors with signalling function, and of by-products of toxicant-induced oxidative damage and of toxicant detoxification pathways^{47,49-51}, their concentration being tightly regulated by a complex redox homeostatic control.

Chemical that are not directly cleared from cells by active efflux proteins⁴⁷ are subjected to biotransformation by oxidative phase I enzymes in the cytoplasm, primarily by cytochrome 450 enzymes – CYPs-, flavoprotein monooxygenase, amine oxidases, xanthine oxidase, frequently followed by phase II reductive or conjugative modification through glutathione-S-transferases (GSTs), UDP-glucuronosyl

transferases (UGTs), catechol-*O*-methyl transferases (COMT), N-acetyl transferases (NATs), epoxide hydrolase, and many others⁵². ROS generated as by-products of phase I reactions are rapidly reduced to non-toxic “physiological” levels by antioxidant enzymes, superoxide dismutase, catalase, glutathione peroxidase, and peroxiredoxins, and by low-molecular weight antioxidants, reduced glutathione, uric acid, ascorbic acid, ceruloplasmin, and others. In case of challenge by higher-than-normal concentrations of exogenous or endogenous toxicants, the interaction with cellular membrane or nuclear receptors induces the expression of an array of stress responsive genes, coding for bio-sensing, signal transmission, and response elements. Superoxide anion-radical, hydrogen peroxide, lipid peroxides, and other ROS come again into play, mediating the activation of two pathways, protein kinase (PKs) cascades, and/or transcription factors (nuclear factor κ B (NF κ B), activator protein-1 (AP-1), and antioxidant response element (ARE)-binding proteins), to start gene transcription and protein synthesis of the phase I, phase II, and antioxidant enzymes^{47,50,51}.

This complex detoxification system is a common target of inherited or functional genetic defects and epigenetic factors. Alterations of the system might lead to incomplete detoxification of exogenous/endogenous toxins or/and to excessive generation of toxic by-products (“Poor Metabolizers” - PM), or to higher-than-normal rates of metabolism, in subjects with hyper-functional genes, possibly duplicated or multiplied (“Extensive Metabolizers” - EM).⁵³ The consequences of these genetic or functional alterations are not univocal, and deserve thorough clinical interpretation, being potentially detrimental or beneficial, depending on the biological function and relative toxicity of the parent compound and of its metabolites. These polymorphisms also affect individual metabolism and resistance towards therapeutic drugs. Further complications for clinical correlation of gene polymorphism with clinical settings occur in the case of detoxifying genes present in multiple classes, requiring multivariate analysis.

Pathogenesis of IEI: Genetic and epigenetic defects of Phase I and II enzymes

In spite of the wealth of studies produced on phase I metabolizing enzymes in the susceptibility to environmentally induced cancers, limited and contradictory information is available on the possible

role of their malfunction in non-tumor environment-associated pathologies. A first case-control research on female Caucasians demonstrated an increased risk for MCS in EM individuals, homozygous for the cytochrome P450 isoform CYP2D6, as compared to PM with inactive gene⁵⁴. The same work documents a possible gene-gene interaction between CYP2D6 and phase II N-acetyl transferase 2 isoform, with consequent elevated risk of MCS development in rapid metabolizers for both enzymes. NAT2 polymorphism and homozygous deletions of M1 and T1 GST genes were again recently significantly correlated with proneness to MCS⁵⁵, confirming that multiple polymorphisms of drug metabolizing enzymes predispose individuals to exaggerated chemical sensitivity⁵³. CYP2D6 isoform is a key enzyme in the metabolism of most anti-depressant and antipsychotic drugs⁵⁶. The PM genotype for CYP2D6 was also proposed as a negative prognostic factor in the development of FM⁵⁷. In spite of the data on genetic and functional peculiarities of drug metabolizing enzymes in MCS subjects^{54,55}, other studies exclude any molecular basis for this condition^{58,59}, claiming inconsistency of results due to limitations in the size of study groups, and methodological bias in patient diagnosis and/or in genetic analysis.

The three main GST families, the soluble ones located in cytosol and mitochondria, and the membrane associated one in microsomes, possess a number of enzymatic and cell signaling regulating functions connected with the detoxification of potential carcinogens and cytotoxic agents⁶⁰. GSTs, and especially GST P1-1, are in fact over-expressed in a variety of malignancies, and correlated to resistance to anticancer agents and chemical carcinogens⁶¹. GSTM1 is strongly connected with the early onset of various diseases based on impaired carcinogen detoxification^{62,63}. GST polymorphisms may reduce glutathione conjugation, one of the major protective mechanisms to modulate reactive metabolite-induced oxidative, and particularly genotoxic damage. Not only individual isoenzymes, but most importantly isoform combinations, contribute to resistance to carcinogens, antitumor drugs, environmental pollutants, and products of oxidative stress. Therefore association of polymorphisms have been correlated with MCS⁵⁵, and more recently with FM⁶⁴. GST cytosolic activity in the olfactory epithelium, the highest in extrahepatic tissues⁶⁵, is of particular

interest for MCS, where the role of odorous triggers is strongly called into play.

Polymorphisms of catechol-*O*-methyl transferase has been investigated in IEI, in connection with the prevalence of neurological symptoms connected with anxiety, memory loss, neuro-muscular pain in IEI, FM and CFS. COMT genetic and epigenetic factors are key biochemical features in the pathologies of the central nervous system with impairment of catecholamine regulation⁶⁶. The most studied COMT gene allelic variants, Val158Met (rs4680), a functional SNP resulting in much higher activity, is linked to the impairment of specific cognitive tasks. In neuropathic and inflammatory pain, new studies⁶⁷ suggest that COMT expression may be regulated through COMT P2 promoter, in the course of nociceptive signaling of NF- κ B. As for IEI, association analysis has revealed a significant excess of the more active COMT allele (472G=V158) related to panic disorder, in particular in female patients⁶⁸. Low COMT activity has been associated with increased pain sensitivity in subjects with perpetuating pain condition⁶⁹. COMT diplotype, indicative for low COMT enzyme activity, has also been shown to increase the risk of chronic pain syndromes, as demonstrated in 63 patients undergoing a standardized fatigue protocol⁷⁰. In a group of 43 CFS patients, SNPs of COMT, neuronal tryptophan hydroxylase-2, and nuclear glucocorticoid receptor NR3C1 allowed prediction of CFS with 76% accuracy⁷¹.

Most of the publications on UDP-glucuronosyl transferase polymorphisms are referred to cancer prevention; few studies have been performed to elucidate their possible role in chemical and nutritional intolerances. UGT isoforms are localized in the inner side of the endoplasmic reticulum membrane, and are committed to catalyze the conjugation with uridine diphospho-glucuronic acid of different xenobiotics and endobiotics, drugs, chemical toxicants, carcinogens, phytochemicals, steroids, bilirubin, thyroid hormones, bile acids, fatty acids, prostaglandins, etc. UGTs are highly expressed in extra-hepatic tissues committed to xenobiotic absorption, distribution, metabolism and excretion, i.e. intestine, esophagus, lung, kidneys, and nasal epithelium⁷².

The activity of three UGT isoforms is influenced by thyroid hormones. This could be relevant to IEI, where a significant incidence of thyroid hormone

dysfunction including autoimmune thyroiditis is observed (unpublished data), or of increase of the stress-sensitive thyroxin hormone⁷³, although some studies deny any role for thyroid hormones^{74,75}. Several other clinical features characteristic for IEI, such as anxiety or depression, and poor quality of life scores may theoretically in part be ascribed to impaired UGT metabolism of thyroid hormones⁷⁶, although no direct evidences are available so far.

Concerning other possible malfunctions of the detoxifying enzymes in IEI, the genetic or acquired alterations of peroxide detoxification deserve special attention. Catalase, selenium-dependent glutathione peroxidases (GPXs) and thioredoxin-dependent peroxidases (peroxiredoxins, PRXs) are crucial enzymes in the protection from oxidative damage generated by hydrogen peroxide and lipid peroxides. Distinct mutations in the catalase gene (the G to A transition at the fifth position of intron 4, a splicing mutation, and the deletion or insertion of nucleotides in the coding regions) result in a complete acatalasemia, bearing severe health outcomes, including increased risk of diabetes mellitus⁷⁷. Detailed epidemiological studies suggested that individuals with lower-than-normal catalase activity are at high risk of the premature onset of age-related degenerative diseases⁷⁸. In view of the growing amount of data available on H₂O₂ and lipid peroxides hyper-production in different environmental intolerances. The role of polymorphisms of catalase, different forms of GPXs and PRXs in the individual susceptibility and in the pathogenesis of non-tumor environmental diseases require further investigation.

Pathogenesis of IEI: Role of oxidative stress and inflammatory mediators

Availability of data concerning the involvement of chronic oxidative damage in the induction and perpetuating of symptoms in functional IEI syndromes has been growing in the last decade, although still limited mainly to CFS and FM conditions. Concerning CFS, early observations documented oxidative damage to DNA and lipids in biopsies from the *vastus lateralis* muscles, associated to adaptive up-regulation of GST activity⁷⁹. Later studies always on patients at rest, registered elevated levels of malonyl dialdehyde⁸⁰, F₂-isoprostanes⁸¹, protein carbonyls⁸², low serum α -tocopherol⁸³, lower-than-normal levels of reduced glutathione (GSH) and cysteine⁸⁴, and lower-than-normal total antioxidant capacity and vitamin E plasma levels, with increased

lipoperoxidation markers, in patients with mild Mg deficiency⁸⁵. Spontaneous and stimulated production of NFkB, cyclo-oxygenase (COX-2) and inducible NO synthase (iNOS) induction in peripheral blood lymphocytes of 18 CFS patients was significantly increased *vs.* matched controls⁸⁴, and correlated to symptom severity score, further documenting the putative role of inflammatory response system and oxidative/nitrosative damage in the underlying mechanism of this functional syndrome²⁶. In the context of redox imbalance, metal ion toxicity has been documented by increased levels of methemoglobin formation in FCS erythrocytes⁸⁶, consistent with the observed impairment of its physiological reducing agents GSH and cysteine. Data on oxidative and nitrosative stress were partly correlated with CFS specific clinical symptoms, although confounding overlapping risk factors, such as obesity⁸¹, hypertension, smoking, were not taken into account in all studies.

Data on oxidative stress in FM are limited and controversial⁸⁷. FM patients were shown to possess peculiar oxidative stress features, such as altered distribution and metabolism of coenzyme Q₁₀ in the blood cells and muscular tissue, with higher than normal plasma concentrations, presumably an adaptive protection mechanism⁸⁸. Significantly increased spontaneous H₂O₂ release from circulating granulocytes⁸⁸, and elevated plasma levels of oxidation markers were reported⁸⁹ and negatively correlated with depression scales. Interestingly, the patterns of redox imbalance and antioxidant protection display relevant differences between FM and CFS, as regards ubiquinol tissue levels and isoprostane urinary excretion, not significantly different in FM group *vs.* controls⁸⁷.

Chronic peroxynitrite hyperproduction has been implicated as a common etiologic factor for CFS, MCS, FM, and post-traumatic stress disorder⁹⁰. Elevated peroxynitrite levels may cause mitochondrial dysfunction, lipid peroxidation and, by positive feedback, elevated pro-inflammatory cytokine levels, in a vicious cycle inducing NO and superoxide production, with additional peroxynitrite formation. Further, the theory is not conflicting with other mechanisms proposed for MCS, namely neural sensitization, neurogenic inflammation and popyrin pathway aberrations⁹¹. This mechanism has been only indirectly confirmed in MCS patients. *In vivo* studies have not as yet unequivocally confirmed the

supposed increased NO levels in FM or CFS or other environmental intolerances.

Cytokine patterns have been analysed in different IEI conditions, and deserve more extensive investigations in those environmental intolerances sharing the frequent features of chronic inflammation with distinct alterations of redox homeostasis. Cytokines may be involved in diverse clinical manifestations of interest for IEI, such as fatigue, fever, sleep, pain, stress, and persistent aching. Functional and biochemical overlapping of IEI with systemic lupus erythematosus⁶ and other autoimmune diseases also sustain the feasibility of an immunologic approach, although currently results for MCS are largely controversial⁹². Dysregulated profiles of pro-inflammatory cytokines have been reported in a number of studies on CFS and FM, with the recurrent feature of chronically increased circulating levels and *ex-vivo* spontaneous release from leukocytes⁹³, also in connection with recurrent sleep loss⁹⁴. Interestingly, impaired TNF- α , IL-6, and heat shock protein release were found in CFS patients following maximal cycling exercise, findings that were positively correlated with plasma TBARS increase⁹⁵.

Current therapeutic approaches and future perspectives

Consequent to the limited knowledge of etio-pathogenetic mechanisms, the environmental borne syndromes here described almost entirely lack clinical *consensus* regarding diagnostic and, most importantly, therapeutic guidelines.

In the present review the most relevant information supporting the hypothesis of an impairment of the chemical defensive system in the onset and clinical course of these chronic invalidating conditions have been collected. IEI most probably bear both genetic and metabolic components. Up-to-date, specific polymorphisms have been identified in the genes encoding for phase I and phase II detoxifying and antioxidant enzymes, and for their receptors and transcription factors, modifying gene activity and regulatory properties, and possibly representing main determinants of individual metabolizing capability. On the other hand, individual peculiarity of adaptive response to chemical stressors may be determined at the epigenetic level through the direct modification of biologically relevant macromolecular targets.

The difficulties connected with genetic screening are related to costs, interpretation and need for more research on innovative drugs delivering appropriate

metabolizing enzymes. Individual capability of adaptive response to chemical stressors may be determined at the epigenetic level through the direct interaction of these substances and their metabolites with biologically important molecules and cellular membranes. Chronically persistent toxic compounds may in fact chemically modify proteins to form auto-antigens, as suspected on the basis of symptom overlapping with classical autoimmune diseases^{6,7}.

The most urging concern about IEI clinical management is the complete lack of targeted drugs, resulting in an unregulated and wide array of experimental protocols, including environmental medicine techniques, holistic therapies, individualized antioxidants or immune modulator nutritional supplements, detoxification techniques, etc. (Table 3). Almost all approaches are devoid of any documented rationale validated *in vivo*, and have never been controlled for safety and efficacy vs. placebo in controlled clinical trials. Based on the limited information so far available, treatments are prescribed in an allegedly individualized fashion. These approaches are often uncorrelated with effective biochemical *status* and genetic predisposition of patients, and not thoroughly followed-up for compliance, efficacy, and adverse effects monitoring.

Since IEI, and in particular multiple chemical sensitivity, are commonly regarded as psychiatric or somatoform disorders, in many countries patients are prescribed psycho-active or pain-killer drugs with antidepressant, anxiolytic, analgesic, myorelaxant actions, without any preventive toxicological screening. Data acquired on polymorphic genes for drug metabolizing enzymes, affecting the metabolic rate for a number of psychotropic medications^{55,56} raise a strong warning on the risk of severe adverse reaction in metabolically impaired patients. However, to our knowledge no studies have monitored so far the frequency of adverse reaction to psychotropic drugs in subjects complying with diagnostic criteria of any of the various IEI. These reactions are frequently occurring, as documented in a study on patients self-reported reactions to treatments in MCS⁹⁶.

Collectively, available data provide indirect evidence that functional or/and genetic defects of endogenous enzymes detoxifying H₂O₂, lipid peroxides or stable toxic products of lipid peroxidation may cause chronic oxidative stress and consequent metabolic alterations characteristic for the patients with IEI. Damage most likely occurs due to

chronic exposure to ambient doses of environmental toxicants, therefore presumably involving specific detoxification pathways, so far still unidentified, displaying very high affinity for low-dose substrates⁹⁷.

Table 3—Main categories of treatments (including non-conventional and self-prescription) reported for idiopathic environmental intolerances (IEI).

Treatment category	Treatment	Disease
Nutritional supplements	Vitamins	MCS
	antioxidants/minerals	all diseases
	raw plant extracts	MCS – FM – FCS
Prescription therapies	Psychotropic drugs	all diseases
	Probiotics	MCS – IBS
	Antimycotics	MCS – CFS
	Antibiotics	MCS
	glutathione	MCS – FM
	hormone replacement	MCS – CFS
	Psychiatric therapies	MCS – GWV
Psychotherapy	psychologic	MCS
	desensitization	
	cognitive-behavioral therapy	MCS – CFS
	relaxation and stress management training	MCS – FM – CFS
	cognitive therapy	MCS
	Family/group therapy	MCS
	Selected food removal	MCS – CFS - IBS
Detoxification treatments	liver/gallbladder flushes	MCS
	metal chelation	MCS – dental amalgam disease
	traditional Chinese herbal medicine	MCS – CFS
	Homeopathic remedies	all diseases
Holistic treatments	diet regimens	all diseases
	Graded exercise therapy	MCS – CFS
Body therapies	aerobic exercise	MCS – FM
	Massage	MCS – CFS
	sauna therapy	MCS – CFS - FM
	Chiropractic	MCS
	Acupuncture	MCS – CFS
Trigger removal	Trigger-free living space	MCS – CFS- IBS- electric hypersensitivity – SBS – SHS
	chemical avoidance	MCS – CFS – SBS – SHS – GWV
	living place antifungal sanitization	MCS – SBS – SHS
	dental amalgam removal	MCS
	working place change or abandon	MCS - electric hypersensitivity

For legend see Table 1

More systematic studies are needed on the regulation, expression, induction, and activity of GPxs, Prxs, catalase and GST isoforms metabolizing 4-hydroxy-2-nonenal, to understand better pathological susceptibility to low-level external stimuli in the subjects suffering from IEL.

In this perspective, any treatment based on antioxidant or chelator principles, able to selectively prevent formation and release of excess reactive species or hydro- or lipid-peroxides, or to enhance specific detoxification pathways through ROS/RNS modulation, is to be taken into consideration for future clinical trials.

References

- Winder C, Mechanism of multiple chemical sensitivity, *Toxicol Lett*, 128 (2002) 85.
- Bornschein S, Förstl H & Zilker T, Idiopathic environmental intolerances (formerly multiple chemical sensitivity) psychiatric perspectives, *J Intern Med*, 250 (2001) 309.
- International Programme on Chemical Safety/World Health Organization (IPCS/WHO). Conclusion and recommendations of a workshop on multiple chemical sensitivities (MCS), *Regu Toxicol Pharmacol*, 24 (1996) S79.
- Wiesmüller G A, Ebel H, Hornberg C, Kwan O & Friel J, Are syndromes in environmental medicine variants of somatoform disorders? *Med Hypotheses*, 61 (2003) 419.
- Kipen H M & Fiedler N, Environmental factors in medically unexplained symptoms and related syndromes: The evidence and the challenge, *Environ Health Perspect*, 110 Suppl. (2002) 597.
- Karlson E W, Watts J, Singorovitch J, Bonetti M, Wright E & Cooper G S, Effect of glutathione S-transferase polymorphisms and proximity to hazardous waste sites on time to systemic lupus erythematosus diagnosis: Results from the Roxbury lupus project, *Arthritis Rheum*, 56 (2007) 244.
- Yun B R, El-Soheby A, Cornelis M C & Bae S C, Glutathione S-transferase M1, T1, and P1 genotypes and rheumatoid arthritis, *J Rheumatol*, 32 (2005) 992.
- Bolt H M & Kiesswetter E, Is multiple chemical sensitivity a clinically defined entity? *Toxicol Lett*, 128 (2002) 99.
- Bornschein S, Förstl H & Zilker T, Idiopathic environmental intolerances (formerly multiple chemical sensitivity) psychiatric perspectives, *J Intern Med*, 250 (2001) 309.
- Mayou R, Somatization, *Psychother Psychom*, 59 (1993) 69.
- Waickman F J & Vojdani A, Putting chemical and environmental sensitivities in perspective. *Otolaryngol Clin North Am*, 31 (1998) 55.
- Yadav S, Zajac E, Singhal S S & Awasthi S, Linking stress-signaling, glutathione metabolism, signaling pathways and xenobiotic transporters. *Cancer Metastasis Rev*, 26 (2007) 59.
- Mattson M P & Cheng A, Neurohormetic phytochemicals: Low-dose toxins that induce adaptive neuronal stress responses, *Trends Neurosci*, 29 (2006) 632.
- Greene G J & Kipen H M, The vomeronasal organ and chemical sensitivity: A hypothesis, *Environ Health Perspect*, 110 Suppl 4 (2002) 655.
- Cullen M R, The worker with multiple chemical sensitivities: An overview, *Occup Med*, 2 (1987) 655.
- Miller C S & Prihoda T J, A controlled comparison of symptoms and chemical intolerances reported by Gulf War veterans, implant recipients and persons with multiple chemical sensitivity, *Toxicol Ind Health*, 15 (1999) 386.
- Bailer J, Witthöft M, Paul C, Bayerl C & Rist F, Evidence for overlap between idiopathic environmental intolerance and somatoform disorders. *Psychosom Med*, 67 (2005) 921.
- Bornschein S, Hausteiner C, Römmelt H, Nowak D, Förstl H & Zilker T, Double-blind placebo-controlled provocation study in patients with subjective multiple chemical sensitivity (MCS) and matched control subjects, *Clin Toxicol (Phila)*, 46 (2008) 443.
- Wolfe F, Smythe H A, Yunus M B, Bennett R M, Bombardier C & Goldenberg D L, The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the multicenter criteria committee, *Arthritis Rheum*, 33 (1990) 160.
- Bradley L A, Pathophysiologic mechanisms of fibromyalgia and its related disorders, *J Clin Psychiatry*, 69 Suppl 2 (2008) 6.
- Buskila D, Genetics of chronic pain states, *Best Pract Res Clin Rheumatol*, 21 (2007) 535.
- Loeser J D, Butler S H, Chapman C R & Turk D C, *Bonica's management of pain*, 4th ed.: (Lippincott Williams and Wilkins, Philadelphia) 2008.
- CDC-Centers for Disease Control and Prevention. <http://www.cdc.gov/cfs/>, 18.11.2008.
- Lorusso L, Mikhaylova S V, Capelli E, Ferrari D, Ngonga G, K & Ricevuti G. Immunological aspects of chronic fatigue syndrome, *Autoimmun Rev*, 8 (2009) 287.
- Moldofsky H, Fibromyalgia, sleep disorder and chronic fatigue syndrome, *Ciba Found Symp*, 173 (1993) 262.
- Maes M, Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms, *Curr Opin Psychiatry*, 22 (2009) 75.
- Mitchell R J, Osborne P B & Haubenreich J E, Dental amalgam restorations: Daily mercury dose and biocompatibility, *J Long Term Eff Med Implants*, 15 (2005) 709.
- Bates M N, Mercury amalgam dental fillings: An epidemiologic assessment, *Int J Hyg Environ Health*, 209 (2006) 309.
- Heyer N J, Echeverria D, Farin F M & Woods J S, The association between serotonin transporter gene promoter polymorphism (5-HTTLPR), self-reported symptoms, and dental mercury exposure, *J Toxicol Environ Health A*, 71 (2008) 1318.
- Reinhardt JW, Side effects: Mercury contribution to body burden from dental amalgam, *Adv Dent Res*, 6 (1992) 110.
- Bergqvist U & Vogel E, *Possible health implications of subjective symptoms and electromagnetic fields* (National Institute for Working Life Solna), 1997, 170.
- Ziskin M C, Electromagnetic hypersensitivity: A COMAR technical information statement, *IEEE Eng Med Biol*, 21 (2002) 173.

- 33 Levallois P, Hypersensitivity of human subjects to environmental electric and magnetic field exposure: A review of the literature, *Environ Health Perspect*, 110 Suppl 4 (2002) 613.
- 34 Havas M, Electromagnetic hypersensitivity: Biological effects of dirty electricity with emphasis on diabetes and multiple sclerosis, *Electromagn Biol Med*, 25 (2006) 259.
- 35 Portier C J & Wolfe M S, *Assessment of health effects from exposure to power-line frequency electric and magnetic fields — NIEHS Working Group Report*, Research Triangle Park (NC): National Institute of Environmental Health Sciences; 1998. NIH publications no 98-3981.
- 36 Hillert L, Berglind N, Arnetz B B & Bellander T, Prevalence of self-reported hypersensitivity to electric or magnetic fields in a population-based questionnaire survey. *Scand J Work Environ Health*, 28 (2002) 33.
- 37 Hillert L, Flato S, Georgellis A, Arnetz B B & Kolmodin-Hedman B, Environmental illness: Fatigue and cholinesterase activity in patients reporting hypersensitivity to electricity, *Environ Res*, 85 (2001) 200.
- 38 Flodin U, Seneby A & Tegenfeldt C, Provocation of electric hypersensitivity under everyday conditions, *Scand J Work Environ Health*, 26 (2000) 93.
- 39 Nieto-Hernandez R, James Rubin G, Cleare A J, Weinman J A & Wessely S, Can evidence change belief? Reported mobile phone sensitivity following individual feedback of an inability to discriminate active from sham signals, *J Psychosom Res*, 65 (2008) 453.
- 40 Levallois P, Hypersensitivity of human subjects to environmental electric and magnetic field exposure: A review of the literature, *Environ Health Perspect*, 110 Suppl 4 (2002) 613.
- 41 Lidén S, "Sensitivity to electricity"-a new environmental epidemic, *Allergy*, 51 (1996) 519.
- 42 Leitgeb N, Schröttner J & Böhm M. Does "electromagnetic pollution" cause illness? An inquiry among Austrian general practitioners, *Wien Med Wochenschr*, 155 (2005) 237.
- 43 Rubin G J, Munshi J D & Wessely S, Electromagnetic hypersensitivity: A systematic Review of provocation studies, *Psychosom Med*, 67(2005) 224.
- 44 Black D W, Okiishi C & Schlosser S, A nine-year follow-up of people diagnosed with multiple chemical sensitivities, *Psychosomatics*, 41 (2000) 253.
- 45 Frick U, Rehm J & Eichhammer P, Risk perception, somatization, and self report of complaints related to electromagnetic fields—a randomized survey study, *Int J Hyg Environ Health*, 205 (2002) 353.
- 46 Ariga K, Ji Q, Hill J P, Kawazoe N & Chen G, Supramolecular approaches to biological therapy, *Expert Opin Biol Ther*, 9 (2009) 307.
- 47 Goldstone J V, Hamdoun A, Cole B J, Howard-Ashby M, Nebert D W & Scally M, The chemical defensome: Environmental sensing and response genes in the *Strongylocentrotus purpuratus* genome, *Dev Biol*, 300 (2006) 366.
- 48 Their R, Brüning T, Roos P H, Rihs H P, Golka K & Ko Y, Markers of genetic susceptibility in human environmental hygiene and toxicology: The role of selected CYP, NAT and GST genes, *Int J Hyg Environ Health*, 206 (2003) 149.
- 49 Korkina L & Pastore S, The role of redox regulation in the normal physiology and inflammatory diseases of skin, *Front Biosci* (Elite Ed), 1 (2009)123.
- 50 Jaiswal A K, Nrf2 signaling in coordinated activation of antioxidant gene expression, *Free Rad Biol Med* 36 (2004) 1199.
- 51 Scandalios J G, Oxidative stress: Molecular perception and transduction of signals triggering antioxidant gene defenses, *Braz J Med Biol Res*, 38 (2005) 995.
- 52 Wourmhoudt L W, Commandeur J N & Vermeulen N P, Genetic polymorphism of human N acetyltransferase, cytochrom P450, glutathione-S-transferase, and epoxide hydrolases emzymes: Relevance to xenobiotic metabolism and toxicity, *Crit Review Toxicol*, 29 (1999) 59.
- 53 Meyer U A, *Drugs in special patient groups: Clinical importance of genomics in drug effects*, edited by Carruthers G S, Hoffmann B B, Melmon K L and Nieremberg D W, (McGraw Hill New York), 2000, 1179.
- 54 McKeown-Eyssen G, Baines C, Cole D E, Riley N, Tyndale R F & Marshall L, Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR, *Int J Epidemiol*, 33 (2004) 971.
- 55 Schnakenberg E, Fabig K R, Stanulla M, Strobl N, Lustig M & Fabig N, A cross-sectional study of self-reported chemical-related sensitivity is associated with gene variants of drug-metabolizing enzymes, *Environ Health*, 6 (2007) 6.
- 56 Scordo M G, Caputi A P, D'Arrigo C, Fava G & Spina E, Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population, *Pharmacol Res*, 50 (2004) 195.
- 57 Skeith K J, Hussain M S, Coutts R T, Ramos-Remus C, Avina-Zubieta J A & Russell A S, Adverse drug reactions and debrisoquine/sparteine (P450IID6) polymorphism in patients with fibromyalgia, *Clin Rheumatol*, 16 (1997) 291.
- 58 Eis D, Helm D, Mühlhous T, Birkner N, Dietel A & Eikmann T, The German multicentre study on multiple chemical sensitivity (MCS), *Int J Hyg Environ Health*, 211 (2008) 658.
- 59 Wiesmüller G A, Niggemann H, Weissbach W, Riley F, Maarouf Z & Dott W, Sequence variations in subjects with self-reported multiple chemical sensitivity (sMCS): A case-control study, *J Toxicol Environ Health A*, 71 (2008) 786.
- 60 Whalen R & Boyer T D, Human glutathione S-transferases, *Semin Liver Dis*, 18 (1998) 345.
- 61 Strange R C & Fryer A A, The glutathione S-transferases: influence of polymorphism on cancer susceptibility, *IARC Sci Publ*, 148 (1999) 231.
- 62 Habdous M, Siest G, Herbeth B, Vincent-Viry M & Visvikis S, Glutathione S-transferases genetic polymorphisms and human diseases: Overview of epidemiological studies. *Ann Biol Clin (Paris)* 62 (2004) 15.
- 63 Bolt H M & Thier R, Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology, *Curr Drug Metab*, 7 (2006) 613.
- 64 Buskila D, Genetics of chronic pain states, *Best Pract Res Clin Rheumatol*, 21 (2007) 535.
- 65 Ben-Arie N, Khen M & Lancet D, Glutathione S-transferases in rat olfactory epithelium: Purification, molecular properties and odorant biotransformation, *Biochem J*, 292 (1993) 379.

- 66 Mannisto P T & Kaakkola S, Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors, *Pharmacol Rev*, 51 (1999) 593.
- 67 Tchivileva I E, Nackley A G, Qian L, Wentworth S, Conrad M & Diatchenko L B, Characterization of NF- κ B-mediated inhibition of catechol-O-methyl transferase, *Mol Pain*, 5 (2009) 13.
- 68 Domschke K, Freitag C M, Kühlenbäumer G, Schirmacher A, Sand P & Nyhuis P, Association of the functional V158M catechol-O-methyl-transferase polymorphism with panic disorder in women, *Int J Neuropsychopharmacol*, 7 (2004) 183.
- 69 Diatchenko L, Slade G D, Nackley A G, Bkhalang K, Sigurdsson A & Belfer I, Genetic basis and individual variations in pain perception and the development of a chronic pain condition, *Hum Mol Genet*, 14 (2005) 135.
- 70 George S Z, Dover G C, Wallace M R, Sack B K, Herbstman D M & Aydog E, Biopsychosocial influence on exercise-induced delayed onset muscle soreness at the shoulder: Pain catastrophizing and catechol-o-methyltransferase (COMT) diplotype predict pain ratings. *Clin J Pain*, 24 (2008) 793.
- 71 Goertzel B N, Pennachin C, de Souza Coelho L, Gurbaxani B, Maloney E M & Jones J F, Combinations of single nucleotide polymorphisms in neuroendocrine effector and receptor genes predict chronic fatigue syndrome, *Pharmacogenomics*, 7 (2006) 475.
- 72 Brierley C H & Burchell B, Human UDP-glucuronosyl transferases: Chemical defence, jaundice and gene therapy, *Bioessays*, 15 (1993) 749.
- 73 Berg M, Arnetz B B, Lidén S, Eneroth P & Kallner A, Techno-stress. A psychophysiological study of employees with VDU-associated skin complaints, *J Occup Med*, 34 (1992) 698.
- 74 Baines C J, McKeown-Eyssen G E, Riley N, Cole D E C, Marshall L & Loescher B, Case-control study of multiple chemical sensitivity, comparing haematology, biochemistry, vitamins and serum volatile organic compound measures, *Occup Med*, 54 (2004) 408.
- 75 Lacoura M, Zunderb T, Schmidtke K, Vaithd P & Scheidta C, Multiple chemical sensitivity syndrome (MCS) – suggestions for an extension of the US MCS-case definition, *Int J Hyg Environ-Health*, 208 (2005) 141.
- 76 Gulseren S, Gulseren L, Hekimsoy Z, Cetinay P, Ozen C & Tokatlioglu B, Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction, *Arch Med Res*, 37 (2006) 133.
- 77 Ogata M, Wang D H & Ogino K, Mammalian acatalasemia: The perspectives of bioinformatics and genetic toxicology, *Acta Med Okayama*, 62 (2008) 345.
- 78 Terlecky S R, Koepke J I & Walton P A, Peroxisomes and aging, *Biochim Biophys Acta*, 1763 (2006) 1749.
- 79 Fulle S, Mecocci P, Fano G, Vecchiet I, Vecchini A & Ricciotti D, Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome, *Free Rad Biol Med*, 29 (2000) 1252.
- 80 Richards R S, Wang L & Jelinek H, Erythrocyte oxidative damage in chronic fatigue syndrome, *Arch Med Res*, 38 (2007) 94.
- 81 Kennedy G, Spence V A, McLaren M, Hill A, Underwood C & Belch J J, Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms, *Free Radic Biol Med*, 39 (2005) 584.
- 82 Smirnova I V & Pall M L, Elevated levels of protein carbonyls in sera of chronic fatigue syndrome patients, *Mol Cell Biochem*, 248 (2003) 93.
- 83 Miwa K & Fujita M, Increased oxidative stress suggested by low serum vitamin E concentrations in patients with chronic fatigue syndrome, *Int J Cardiol*, 136 (2009) 238.
- 84 Maes M, Mihaylova I, Kubera M & Bosmans E, Not in the mind but in the cell: Increased production of cyclooxygenase-2 and inducible NO synthase in chronic fatigue syndrome, *Neuro Endocrinol Lett*, 28 (2007) 463.
- 85 Manuel y Keenoy B, Moorkens G, Vertommen J, Noe M, Nève J & De Leeuw I, Magnesium status and parameters of the oxidant-antioxidant balance in patients with chronic fatigue: Effects of supplementation with magnesium, *J Am Coll Nutr*, 19 (2000) 374.
- 86 Logan A C & Wong C, Chronic fatigue syndrome: Oxidative stress and dietary modifications, *Altern Med Rev*, 6 (2001) 450.
- 87 Chung C P, Titova D, Oeser A, Randels M, Avalos I, Milne G L, Morrow J D & Stein C M, Oxidative stress in fibromyalgia and its relationship to symptoms, *Clin Rheumatol*, 28 (2009) 435.
- 88 Cordero M D, Moreno-Fernandez A M, deMiguel M, Bonal P, Campa F, Jimenez-Jimenez L M & Ruiz-Losada A, Coenzyme Q₁₀ distribution in blood is altered in patients with fibromyalgia, *Clin Biochem*, 42 (2009) 732.
- 89 Bagis S, Tamer L, Sahin G, Bilgin R, Guler H & Ercan B, Free radicals and antioxidants in primary fibromyalgia: An oxidative stress disorder? *Rheumatol Int*, 25 (2005) 188.
- 90 Pall M L, Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite, *Med Hypotheses*, 57 (2001) 139.
- 91 Pall M L, Elevated nitric oxide/peroxynitrite theory of multiple chemical sensitivity: Central role of N-methyl-D-aspartate receptors in the sensitivity mechanism, *Environ Health Perspect*, 111 (2003) 1461.
- 92 Simon G E, Daniell W, Stockbridge H, Claypoole K & Rosenstock L, Immunologic, psychological, and neuropsychological factors in multiple chemical sensitivity. A controlled study, *Ann Intern Med*, 119 (1993) 97.
- 93 Patarca R, Cytokines and chronic fatigue syndrome, *Ann N Y Acad Sci*, 933 (2001) 185.
- 94 Dearman R J & Kimber I, Cytokine profiling and chemical allergy, *Toxicol Appl Pharmacol*, 185 (2002) 228.
- 95 Jammes Y, Steinberg J G, Delliaux S & Brégeon F, Chronic fatigue syndrome combines increased exercise induced oxidative stress and reduced cytokine and Hsp responses, *J Intern Med*, 266 (2004) 196.
- 96 Gibson P R, Elms A N & Ruding L A, Perceived treatment efficacy for conventional and alternative therapies reported by persons with multiple chemical sensitivity, *Environ Health Perspect*, 111 (2003) 1498.
- 97 Rappaport S M, Kim S, Lan Q, Vermeulen R, Waidyanatha S & Zhang L, Evidence that humans metabolize benzene via two pathways, *Environ Health Perspect*, 117 (2009) 946.